Propranolol

Propranolol is a nonselective beta blocker, meaning it competitively antagonizes both the beta-1 and beta-2 subtypes of the adrenergic receptor ^[1][2]. It is a lipophilic molecule that readily crosses the blood-brain barrier, reaching far higher concentrations in the brain than in the blood, which underlies several of its central nervous system effects ^[2]. The commercial drug is a racemic mixture of two mirror-image forms, of which the S enantiomer carries almost all of the beta-blocking activity ^[2]. It is usually supplied as the hydrochloride salt.

The drug was created by Sir James Black and colleagues at ICI Pharmaceuticals and reached the market in the mid-1960s, initially for angina pectoris ^[1]. It was the first beta blocker used successfully against angina and high blood pressure, and Black's insight that blocking beta-adrenergic receptors could ease the heart's workload was a landmark in rational drug design that contributed to his Nobel Prize in Physiology or Medicine ^[1]. In the decades that followed, a long series of further uses was uncovered, and new indications continue to emerge for what is now an inexpensive, off-patent medicine ^[1].

Propranolol is used across a broad range of conditions. In cardiovascular medicine it treats hypertension, angina, certain arrhythmias, and the aftermath of heart attack, and it lowers pressure in the portal vein to help prevent variceal bleeding ^[1]. It is a well-established preventive treatment for migraine; a Cochrane review of 58 trials involving more than five thousand participants concluded that propranolol is clearly more effective than placebo for short-term migraine prophylaxis and roughly as effective as several comparator drugs ^[3]. It is also used for essential tremor, overactive thyroid and thyroid storm, pheochromocytoma, and the physical symptoms of performance and situational anxiety, where it blunts the racing heart and tremor of the adrenaline response ^[1]. A striking modern application is infantile hemangioma: after the effect was noticed by chance, propranolol became the first-line drug for these common vascular birthmarks of infancy, largely displacing corticosteroids ^[4].

Propranolol is a prescription-only medicine in the United States, United Kingdom, European Union, and elsewhere, and it appears on the World Health Organization Model List of Essential Medicines ^[1][2]. It was first sold under the brand name Inderal and is now available generically and under many trade names, including a pediatric oral solution licensed specifically for infantile hemangioma ^[2][4]. Formulations include immediate-release and long-acting oral tablets and capsules as well as an intravenous preparation, and the drug is broken down in the liver by the enzymes CYP2D6, CYP1A2, and CYP2C19 ^[2].

Propranolol is a non-selective beta-blocker that slows heart rate and lowers blood pressure, causing fatigue, dizziness, and cold hands and feet, and it can provoke bronchospasm, making it contraindicated in asthma. It can mask the warning signs of low blood sugar in people with diabetes and should never be stopped abruptly, as rebound rises in heart rate and blood pressure can trigger angina or dangerous cardiac events. It is contraindicated in certain slow-heart-rate rhythms and decompensated heart failure and requires care in those with these conditions.

Propranolol is metabolized by CYP2D6 and CYP1A2, so inhibitors such as fluoxetine, paroxetine or quinidine (CYP2D6) and fluvoxamine (CYP1A2) raise its plasma levels and can intensify bradycardia and hypotension. Combined with non-dihydropyridine calcium channel blockers such as verapamil or diltiazem, or with digoxin, it produces additive AV-nodal suppression and risk of heart block. As a non-selective beta-blocker it can provoke bronchospasm and is contraindicated in asthma, and it both masks the adrenergic warning signs of hypoglycemia and blunts recovery in patients on insulin or sulfonylureas. NSAIDs can attenuate its antihypertensive effect, and abrupt withdrawal alongside clonidine can precipitate rebound hypertension. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Propranolol was created in the early 1960s by the British scientist James Black and colleagues at Imperial Chemical Industries, the culmination of a deliberate effort to design a drug that would block the actions of adrenaline on the heart. It was the first clinically successful beta-adrenergic receptor antagonist, a breakthrough that transformed the treatment of angina, hypertension and cardiac arrhythmias and for which Black was awarded the Nobel Prize in Physiology or Medicine in 1988.

In the decades that followed, its uses expanded far beyond the heart to include migraine prevention, essential tremor and the physical symptoms of performance anxiety. A striking new application emerged serendipitously in 2008, when French physicians led by Léauté-Labrèze observed that propranolol dramatically shrank infantile hemangiomas, an accidental discovery that quickly became the first effective drug therapy for these common vascular tumors. Propranolol appears on the World Health Organization list of essential medicines and remains a foundational cardiovascular drug.

Propranolol is a landmark medicine, the original beta-blocker and one of the most influential drugs of the twentieth century, its inventor honored with a Nobel Prize. Physicians across many specialties rely on it, and patients appreciate its remarkable versatility, from steadying a racing heart and easing migraines to quieting the trembling hands and pounding pulse of stage fright. Its reputation was renewed dramatically when it became the first effective treatment for infantile hemangioma, sparing many children from surgery.

Modern reviews are candid that its benefits in hemangioma involve incomplete tumor suppression and off-target effects, and that as a nonselective agent it must be avoided in asthma and used carefully in certain patients. Even with these caveats, its inclusion on the WHO essential medicines list and its enduring place in cardiology, neurology and dermatology confirm its standing as a genuinely essential and trusted drug.